<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2651</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">http://dx.doi.org/10.31782/IJCRR.2020.12031</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Effect of N-acetylcysteine in Indeterminate Acute Liver Failure&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nabi</surname><given-names>Tauseef</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dar</surname><given-names>Sajad Ahmad</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rafiq</surname><given-names>Nadeema</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>10</day><month>02</month><year>2020</year></pub-date><volume>)</volume><issue/><fpage>1</fpage><lpage>6</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Background: Acute liver failure (ALF) is a rare syndrome, characterized by acute derangement of liver function and carries high mortality. Indeterminate ALF still forms a significant number of cases in India as well in the world. A prospective case-control study was carried with the aim to determine the effect of N-Acetylcysteine (NAC) on the survival of indeterminate ALF patients.&#13;
Methods: A total of 30 patients with a diagnosis of indeterminate ALF were included in the study. 14 patients received NAC infusion for 72hrs whereas 16 patients in control group received placebo. The parameters evaluated were demographic, clinical, biochemical, outcome and length of hospital stay.&#13;
Results: The two groups were comparable for the various baseline characteristics (demographic, clinical, biochemical etc.). A total of 18 of 30 (60%) patients died with ALF complications; 6 (42.8%) patients belonged to NAC group and 12 (75%) patients to Control group (P = 0.077). The overall survival was not improved by NAC in indeterminate ALF. Use of NAC also did not reduce the duration of hospital stay of survived patients (P = 0.409).&#13;
Conclusion: The overall survival was not improved by NAC in indeterminate ALF. NAC administration did not reduce the duration of hospital stay.&#13;
</p></abstract><kwd-group><kwd>Acute Liver Failure (ALF)</kwd><kwd> Indeterminate ALF</kwd><kwd> Hepatic encephalopathy (HE)</kwd><kwd> N-Acetylcysteine (NAC)</kwd></kwd-group></article-meta></front></article>
